Public source
Reviewed 11 May 2026
Completeness Fair (28%)
The CS-PDL1 algorithm is intended for cancer screening in lung tissue samples: - Detection of cells positive for the PDL1 antibody. - Assists in diagnosing pathological conditions related to the presence of the PDL1 antibody. - Provides specific information about a physiological or pathological state. - A quantitative automated algorithm that integrates Artificial Intelligence. - Uses lung tissue samples from patients of any gender and age. Therefore, the purpose of the algorithm is to provide the pathologist or healthcare professional using it with an automatic identification of findings, facilitating the interpretation of areas with cancer on an image of a processed lung tissue sample. This is achieved by highlighting potential areas of interest so that the pathologist can make a faster and safer diagnosis, less influenced by inter-observer variability since it is standardized. The diagnosis provided by the algorithm is not definitive: it must always be validated by the pathologist, who confirms the accuracy of the generated information.
No papers to support — we monitor for new evidence.
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Not specified
Staining
Stain subtype
Regulatory Information
Pathway:
In Vitro Diagnostic Directive (IVDD)
Class:
General IVD Devices
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
No research papers or evidence on file yet.
The registry monitors publications for new evidence.
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Source: Public | First published: Apr 23, 2026 | Last updated: May 11, 2026